Gut Liver.  2017 Mar;11(2):226-231. 10.5009/gnl16099.

Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease

Affiliations
  • 1Department of Internal Medicine, Seoul National University Hospital, Healthcare System Gangnam Center, Healthcare Research Institute, Seoul, Korea.
  • 2Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea. harley1333@hanmail.net
  • 3Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • 4Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.
  • 5Department of Internal Medicine, Inje University College of Medicine, Busan, Korea.
  • 6Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea.
  • 7Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
  • 8Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
  • 9Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.
  • 10Department of Internal Medicine, The Catholic University of Korea College of Medicine, Bucheon, Korea.
  • 11Department of Internal Medicine, Konyang University College of Medicine, Daejeon, Korea.
  • 12Department of Internal Medicine, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
  • 13Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.
  • 14Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea.
  • 15Medical Research Collaborating Center, Seoul National University Hospital and Seoul National University College of Medicine, Seoul, Korea.
  • 16Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.

Abstract

BACKGROUND/AIMS
The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease.
METHODS
Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed.
RESULTS
The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/gastroduodenal ulcer, 68.8%, p=0.655).
CONCLUSIONS
Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.

Keyword

Levofloxacin; Helicobacter pylori; Third-line eradication
Full Text Links
  • GNL
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr